ME02756B - Fuziona belančevina protiv raka - Google Patents

Fuziona belančevina protiv raka

Info

Publication number: ME02756B
Authority: ME; Montenegro
Prior art keywords: fusion protein; cancer fusion; cancer; protein; fusion
Prior art date: 2011-01-05

Application number

MEP-2017-131A

Other languages

German (de)

English (en)

French (fr)

Inventor

Jerzy Szczepan Pieczykolan

Sebastian Dominik Pawlak

Bartlomiej Maciej Zerek

Piotr Kamil Rózga

Original Assignee

Adamed Sp Zoo

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-01-05

Filing date

2012-01-05

Publication date

2018-01-20

2012-01-05 Application filed by Adamed Sp Zoo filed Critical Adamed Sp Zoo

2018-01-20 Publication of ME02756B publication Critical patent/ME02756B/me

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/49—Platelet-derived growth factor [PDGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/515—Angiogenesic factors; Angiogenin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Vascular Medicine (AREA)
Cell Biology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Chemical Kinetics & Catalysis (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

MEP-2017-131A 2011-01-05 2012-01-05 Fuziona belančevina protiv raka ME02756B (me)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
PL393578A PL219845B1 (pl)	2011-01-05	2011-01-05	Przeciwnowotworowe białko fuzyjne
EP12700215.2A EP2661496B1 (en)	2011-01-05	2012-01-05	Anticancer fusion protein
PCT/EP2012/050145 WO2012093158A1 (en)	2011-01-05	2012-01-05	Anticancer fusion protein

Publications (1)

Publication Number	Publication Date
ME02756B true ME02756B (me)	2018-01-20

Family

ID=45476512

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-2017-131A ME02756B (me)	2011-01-05	2012-01-05	Fuziona belančevina protiv raka

Country Status (27)

Country	Link
US (1)	US9175059B2 (me)
EP (1)	EP2661496B1 (me)
JP (1)	JP5797773B2 (me)
KR (1)	KR101950043B1 (me)
CN (1)	CN103228788B (me)
AU (1)	AU2012204900B2 (me)
BR (1)	BR112013016980B1 (me)
CA (1)	CA2814597C (me)
CY (1)	CY1119149T1 (me)
DK (1)	DK2661496T3 (me)
EA (1)	EA025830B1 (me)
ES (1)	ES2628377T3 (me)
HR (1)	HRP20170905T1 (me)
HU (1)	HUE032576T2 (me)
IL (1)	IL226205B (me)
LT (1)	LT2661496T (me)
ME (1)	ME02756B (me)
MX (1)	MX339203B (me)
PH (1)	PH12013500715A1 (me)
PL (2)	PL219845B1 (me)
PT (1)	PT2661496T (me)
RS (1)	RS56095B1 (me)
SG (1)	SG190049A1 (me)
SI (1)	SI2661496T1 (me)
SM (1)	SMT201700300T1 (me)
UA (1)	UA108778C2 (me)
WO (1)	WO2012093158A1 (me)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LT2970487T (lt)	2013-03-12	2020-05-11	Molecular Templates, Inc.	Citotoksiniai baltymai, apimantys tikslinių ląstelių rišimosi sritis ir shiga toksino subvienetų sritis, skirtas selektyviam tam tikrų rūšių ląstelių žudymui
WO2014141094A1 (en)	2013-03-14	2014-09-18	Adamed Sp. Z O.O.	Anticancer conjugate
JP2016520053A (ja) *	2013-05-06	2016-07-11	中国▲薬▼科大学ＣｈｉｎａＰｈａｒｍａｃｅｕｔｉｃａｌＵｎｉｖｅｒｓｉｔｙ	腫瘍微小環境における血管再生の抑制及び適応免疫応答の活性化を有する二機能の融合タンパク質及びその遺伝子並びに使用
AU2015209065C1 (en)	2014-01-27	2019-09-26	Molecular Templates, Inc.	De-immunized Shiga toxin A Subunit effector polypeptides for applications in mammals
CA2937524A1 (en)	2014-02-05	2015-08-13	Molecular Templates, Inc.	Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
US11142584B2 (en)	2014-03-11	2021-10-12	Molecular Templates, Inc.	CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
KR102496206B1 (ko)	2014-06-11	2023-02-06	몰레큘러 템플레이츠, 인코퍼레이션.	프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자
EP3253799B1 (en)	2015-02-05	2020-12-02	Molecular Templates, Inc.	Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
US10428132B2 (en)	2015-02-11	2019-10-01	West China Hospital, Sichuan University	Tumor necrosis factor-related apoptosis-inducing ligand variant, as well as a preparation method and use thereof
SMT202000226T1 (it)	2015-05-30	2020-05-08	Molecular Templates Inc	Impalcatura di subunita' a della tossina shiga de-immunizzate e molecole di targeting cellulare comprendenti la stessa
CA3043333A1 (en)	2016-12-07	2018-06-14	Molecular Templates, Inc.	Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
WO2018140427A1 (en)	2017-01-25	2018-08-02	Molecular Templates, Inc.	Cell-targeting molecules comprising de-immunized, shiga toxin a subunit effectors and cd8+ t-cell epitopes
CN110612117B (zh)	2018-04-17	2024-04-12	分子模板公司	包含去免疫化的志贺毒素a亚基支架的her2靶向分子

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU676476B2 (en)	1992-04-29	1997-03-13	Georgetown University	Binding peptides which interact with ligand growth factors of the epidermal growth factor receptor and erbB-2-receptor
KR101004174B1 (ko)	1995-06-29	2010-12-24	임뮤넥스 코포레이션	세포소멸을 유도하는 시토킨
JPH11513249A (ja) *	1995-09-27	1999-11-16	メディカル・リサーチ・カウンシル	プロテアーゼにより開裂可能なタンパク質を組込んだ組換えウイルス
US7786282B2 (en) *	2001-12-06	2010-08-31	The Regents Of The University Of California	Nucleic acid molecules encoding TNF-α ligand polypeptides having a CD154 domain
DE10247755B4 (de) *	2002-10-14	2006-01-19	Pfizenmaier, Klaus, Prof. Dr.	Selektive, lokale Aktivierung von Mitgliedern der TNF-Rezeptorfamilie durch systemisch inaktive nicht-Antikörper-TNF-Liganden-Fusionsproteine
CN1257187C (zh) *	2003-10-22	2006-05-24	上海恰尔生物技术有限公司	钙网蛋白－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
US7431915B2 (en) *	2003-10-31	2008-10-07	The Regents Of The University Of California	Peptides whose uptake by cells is controllable
WO2005042744A1 (fr)	2003-11-03	2005-05-12	Beijing Sunbio Biotech Co., Ltd.	Proteine de recombinaison anticancereuse, ses genes codant et ses utilisations
CN1256347C (zh) *	2003-12-10	2006-05-17	中国人民解放军第二军医大学	激肽原第五结构域－肿瘤坏死因子相关凋亡诱导配体的融合蛋白及其制法和用途
ZA200800974B (en)	2005-08-16	2009-11-25	Genentech Inc	Apoptosis sensitivity to Apo2L/TRAIL by testing for 'GalNac-T14 expression in cells/tissues
WO2009002947A2 (en)	2007-06-22	2008-12-31	Affymax, Inc.	Compounds and peptides that bind the trail receptor
GB0723059D0 (en)	2007-11-23	2008-01-02	Nat Univ Ireland	Improved cytokine design
GB0724532D0 (en)	2007-12-17	2008-01-30	Nat Univ Ireland	Trail variants for treating cancer
TW200950778A (en)	2008-05-14	2009-12-16	Genentech Inc	Methods of using Apo2L/TRAIL to treat cancer
EP2297198B1 (en) *	2008-06-30	2014-12-17	University Of Pennsylvania	Fn14/trail fusion proteins
PL391627A1 (pl) *	2010-06-25	2012-01-02	Adamed Spółka Z Ograniczoną Odpowiedzialnością	Przeciwnowotworowe białko fuzyjne
NZ609216A (en) *	2010-12-03	2014-05-30	Adamed Sp Zoo	Anticancer fusion protein

2011
- 2011-01-05 PL PL393578A patent/PL219845B1/pl unknown
2012
- 2012-01-05 EP EP12700215.2A patent/EP2661496B1/en active Active
- 2012-01-05 RS RS20170597A patent/RS56095B1/sr unknown
- 2012-01-05 WO PCT/EP2012/050145 patent/WO2012093158A1/en active Application Filing
- 2012-01-05 AU AU2012204900A patent/AU2012204900B2/en active Active
- 2012-01-05 PT PT127002152T patent/PT2661496T/pt unknown
- 2012-01-05 CN CN201280003863.3A patent/CN103228788B/zh active Active
- 2012-01-05 HU HUE12700215A patent/HUE032576T2/en unknown
- 2012-01-05 PL PL12700215T patent/PL2661496T3/pl unknown
- 2012-01-05 KR KR1020137020558A patent/KR101950043B1/ko active IP Right Grant
- 2012-01-05 ES ES12700215.2T patent/ES2628377T3/es active Active
- 2012-01-05 SG SG2013032768A patent/SG190049A1/en unknown
- 2012-01-05 CA CA2814597A patent/CA2814597C/en active Active
- 2012-01-05 SI SI201230978T patent/SI2661496T1/sl unknown
- 2012-01-05 DK DK12700215.2T patent/DK2661496T3/en active
- 2012-01-05 MX MX2013007872A patent/MX339203B/es active IP Right Grant
- 2012-01-05 EA EA201391005A patent/EA025830B1/ru unknown
- 2012-01-05 US US13/978,090 patent/US9175059B2/en active Active
- 2012-01-05 JP JP2013547859A patent/JP5797773B2/ja active Active
- 2012-01-05 BR BR112013016980-0A patent/BR112013016980B1/pt active IP Right Grant
- 2012-01-05 LT LTEP12700215.2T patent/LT2661496T/lt unknown
- 2012-01-05 ME MEP-2017-131A patent/ME02756B/me unknown
- 2012-01-05 SM SM20170300T patent/SMT201700300T1/it unknown
- 2012-01-05 PH PH1/2013/500715A patent/PH12013500715A1/en unknown
- 2012-05-01 UA UAA201309548A patent/UA108778C2/ru unknown
2013
- 2013-05-07 IL IL226205A patent/IL226205B/en active IP Right Grant
2017
- 2017-06-13 HR HRP20170905TT patent/HRP20170905T1/hr unknown
- 2017-06-15 CY CY20171100632T patent/CY1119149T1/el unknown

Also Published As

Publication number	Publication date
CN103228788A (zh)	2013-07-31
CA2814597C (en)	2019-01-08
DK2661496T3 (en)	2017-07-03
SG190049A1 (en)	2013-06-28
LT2661496T (lt)	2017-07-10
NZ609219A (en)	2014-06-27
WO2012093158A1 (en)	2012-07-12
PL393578A1 (pl)	2012-07-16
SMT201700300T1 (it)	2017-07-18
US9175059B2 (en)	2015-11-03
ES2628377T3 (es)	2017-08-02
EP2661496A1 (en)	2013-11-13
CN103228788B (zh)	2016-09-07
BR112013016980A2 (pt)	2020-08-04
UA108778C2 (xx)	2015-06-10
RS56095B1 (sr)	2017-10-31
HUE032576T2 (en)	2017-09-28
EA201391005A1 (ru)	2013-11-29
IL226205B (en)	2018-10-31
EA025830B1 (ru)	2017-02-28
US20130288963A1 (en)	2013-10-31
HRP20170905T1 (hr)	2017-09-08
MX339203B (es)	2016-05-13
JP2014504868A (ja)	2014-02-27
KR20140036143A (ko)	2014-03-25
SI2661496T1 (sl)	2017-09-29
CY1119149T1 (el)	2018-02-14
MX2013007872A (es)	2013-07-30
JP5797773B2 (ja)	2015-10-21
IL226205A0 (en)	2013-07-31
CA2814597A1 (en)	2012-07-12
BR112013016980B1 (pt)	2022-10-11
AU2012204900B2 (en)	2014-12-18
AU2012204900A1 (en)	2013-05-02
PH12013500715A1 (en)	2013-06-10
EP2661496B1 (en)	2017-03-15
KR101950043B1 (ko)	2019-02-19
PT2661496T (pt)	2017-06-26
PL2661496T3 (pl)	2017-08-31
PL219845B1 (pl)	2015-07-31

Publication	Publication Date	Title
HUS2300021I1 (hu)	2023-07-28	Anti-IL-36R antitestek
CY2024011I2 (el)	2024-12-13	Αντισωματα anti-fcrn
HRP20150241T1 (xx)	2015-06-05	Antikancerogeni fuzijski protein
EP2714735A4 (en)	2014-12-31	SPECIFIC ANTIBODIES OF TGF BETA
DK2934584T3 (da)	2020-05-18	Anti-gdf15-antistoffer
CO6811812A2 (es)	2013-12-16	Anticuerpo anti-b7-h3
EP2758080A4 (en)	2015-03-11	ANTICANCER IMMUNOTHERAPY
ME02756B (me)	2018-01-20	Fuziona belančevina protiv raka
BR112014004902A2 (pt)	2017-07-04	peptídeos
HK1192587A1 (zh)	2014-08-22	治療性融合蛋白
CO6900146A2 (es)	2014-03-20	Imidazopiridazinas sustituidas con amino
CR20140127A (es)	2014-08-20	Anticuerpo anti-abtcr
PL2663506T3 (pl)	2016-03-31	Zamknięcie
IL231616A0 (en)	2014-05-28	Tropicalizing agent
IL232834A0 (en)	2014-07-31	Anti-cancer fusion protein
SMT201500203B (it)	2015-10-30	Proteina di fusione anticancro
EP2698386A4 (en)	2014-12-03	FUSION PROTEIN
DK2828292T3 (da)	2019-01-02	Jcv-neutraliserende antistoffer
DK2935330T3 (da)	2019-07-22	Anti-notch3-antistoffer
DK3521315T3 (da)	2020-11-09	Anti-transglutaminase-2-antistoffer
CO6841994A2 (es)	2014-01-20	Anticuerpos
EP2793918A4 (en)	2015-11-18	HDC-SIGN LINK PEPTIDES
LT2742068T (lt)	2019-07-10	Nauji antikūnai prieš fosforilcholiną
EP2746767A4 (en)	2015-01-21	MICROCHIP
FR2970312B1 (fr)	2013-10-11	Joint semi-ondule